Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Prostate cancer
      • Bladder cancer
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • Media
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
    • Our annual accounts
    • Pelican Cancer Foundation – What next?
    • Support Us
    • Job opportunities
    • Partners
  • Workshops
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Videos
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Prostate Cancer Research
      • Focal therapy and HIFU research
      • MRI research for prostate cancer
      • Prostate cancer colloquiums
      • FORECAST
      • Trachtomap
      • Papers of interest
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Bladder cancer research
      • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Jay’s story (bladder cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Prostate cancer
      • Our prostate cancer team
      • Prostate cancer treatment options
      • Pelican’s position
    • Bladder cancer
      • Blue light cystoscopy
      • Bladder cancer – useful contacts
    • Pseudomyxoma peritonei
    • Kidney cancer
      • Our kidney cancer team
      • Kidney cancer – useful contacts
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
      • How your donations are spent
    • Fundraising
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
      • Our events
    • Leaving a Legacy
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Charity of the Year partnerships
    • Pelican Film Society
  • Shop
  • Events
  • Contact us

Green light laser

New Green Light PVP: a procedure for the treatment of benign prostate enlargement.

The recent acquisition of this new laser system offers the large number of men with symptoms due to benign prostate enlargement (BPH) an alternative to standard surgical treatment for this common non-cancerous condition.

The advantages of this new technique are that it is ‘minimally-invasive’ and can be performed as a day-case procedure with very few complications. Using ‘cutting edge’ technology, high power laser energy is delivered to the obstructing prostate tissue causing the tissue to vapourise without significant bleeding. This laser is one of the first of its kind in the south of England and given the excellent early results it is likely it will soon become the treatment of choice for men with troublesome urinary symptoms.

Men with benign enlargement of the prostate may suffer from obstruction to the flow of urine through the water pipe (urethra). This is due to swelling or enlargement of the prostate such that the bladder has to work under pressure to expel the urine. This gives rise to problems with urination and in some cases this may result in a complete stoppage with a painful inability to pass urine.

Most commonly, however, men present to their practitioners with varied lower urinary tract symptoms; urgency, frequency of urination, difficulty starting, poor flow and dribbling. If mild, these symptoms can be treated by medication, but if this fails or if symptoms are severe or if a complete stoppage occurs, then surgery is usually necessary.

The traditional surgical procedure involved coring out of the passage through the prostate by passing equipment up the urethra. This operation is called trans-urethral resection of the prostate (TURP) and it has been the preferred operation for the last 25 years with over 50,000 such operations carried out every year in the UK.

The long term results of this operation are very good but men are usually in hospital for 3 days and a catheter is kept in place for 1-2 days following surgery and the risk of bleeding requiring a blood transfusion is in the order of 5%.

Lasers have been used for a number of years but the results have never been sufficiently good to displace TURP as it has not been easy to get the procedure down to a daycase episode, furthermore some patients complained of pain passing water for a few weeks following the operation.

With recent technological advances the new generation high power KTP laser ‘Greenlight PVP’ represents a very significant challenge to the ‘gold standard’ status of TURP.

Why is this new treatment so good?

This laser system is able to deliver a very powerful modulated KTP-YAG laser beam which is absorbed by the haemoglobin pigment in tissue. This causes massive localised heating of the prostate tissue resulting in instantaneous vaporisation with virtually no bleeding. The laser is also passed up the urethra and so there are no ‘cuts’.

The advantages of photoselective vaporisation (PVP) of the prostate are outlined below:

  • No cases of impotence have been reported following this operation (for TURP this is the case for as many as 1 in 7 men)
  • It is less likely to cause any change to the amount of ejaculatory fluid produced during sex
  • Bleeding is rare and so patients do not need to stop tablets such as aspirin before surgery
  • The majority of patients are home within 24 hours and so this is truly a day-case procedure
  • If a catheter is sited after the procedure, it may be removed later the same day or the following day
  • There is no limit to the size of prostate that can be treated this way
  • Men otherwise deemed unfit for traditional surgery such as TURP are likely to be able to have this new alternative treatment

This operation is usually performed under a general anaesthetic and takes about 1 hour with at least three of these operations currently being performed each week at the North Hampshire Hospital and the Hampshire Clinic.

Pelican Cancer Foundation Follow

Driving innovation and advancing surgery to help patients live well, for longer.

Pelican_Cancer
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
15h

🎥The future challenges for colorectal cancer management
👇 Available to watch now - http://pelicancancervideos.org

Reply on Twitter 1557246868060520448 Retweet on Twitter 1557246868060520448 2 Like on Twitter 1557246868060520448 4 Twitter 1557246868060520448
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
9 Aug

👇 Available to watch now - http://pelicancancervideos.org
🎥The future challenges for colorectal cancer management

Fourth and final session with Prof Phil Quirke, Prof Heald and Mr Moran @Brendan92855812 @ProfessorHeald in our series Milestones in Managing and Curing Rectal Cancer.

Reply on Twitter 1556881711698325504 Retweet on Twitter 1556881711698325504 5 Like on Twitter 1556881711698325504 7 Twitter 1556881711698325504
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
4 Aug

Book now to attend the KHP Kent & Hampshire Hospitals NET Centre 9th Annual Meeting - discussing the management of patients with neuroendocrine tumours

Convened by Dr. Raj Srirajaskanthan & Professor John Ramage

14/10/2022, 10 - 5pm, London - SE5 8BB
http://netninthannualmeeting.eventbrite.co.uk

Reply on Twitter 1555070527651209217 Retweet on Twitter 1555070527651209217 1 Like on Twitter 1555070527651209217 1 Twitter 1555070527651209217
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2022 · Outreach Pro Theme on Genesis Framework · WordPress · Log in